
Mark Garofoli, director of Experiential Learning Program at WVU School of Pharmacy, discusses his CPhT 2021 conference presentation regarding the role and impact of pharmacy technicians on opioids in the pharmacy.

Mark Garofoli, director of Experiential Learning Program at WVU School of Pharmacy, discusses his CPhT 2021 conference presentation regarding the role and impact of pharmacy technicians on opioids in the pharmacy.

Linda Mendonça, DNP, RN, PHNA-BC, president of the National Association of School Nurses, discusses a new poll released by the COVID-19 Vaccine Education and Equity Project and the National Association of School Nurses about parents’ plans to vaccinate their school-aged children.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, on his recent presentations at Insight 2021 and the virtual Sana Symposium on psychedelic adverse effects and drug-drug interactions.

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDE, focuses on the safety and efficacy of systemic agents used to treat atopic dermatitis.

Emily Holcomb, PharmD, BCPS, ISMP Safe Medication Management Fellow, discusses her CPhT 2021 conference presentation regarding targeted medication safety best practices.

Nathan Bryson, PhD, chief scientific officer of Field Trip Health, said the company's new psychedelic compound, FT-104, could have potential uses in the treatment of postpartum depression.

In addition, some parents may still be unvaccinated, so counseling them on the safety and efficacy of the vaccines is important.

Gyang and Hansen discussed any new or existing treatment options for patients, the role of the pharmacist changing, and what they wish others knew about MS.

Paula Durlofsky, PhD, a writer for the American Psychological Association's Device Management and Digital Intelligence committee discusses how social media has impacted the mental health of health care professionals in recent years, including the COVID-19 Pandemic.

Bhavesh Shah, RPh, BCOP, and Thomasina Morris, RPh, MHA, BCOP, discuss toxicities to monitor for when using PARP inhibitors to battle ovarian cancer.

The Keep Up the Rates campaign is aiming to encourage patients to catch up on routine vaccinations that might have been missed or delayed due to the COVID-19 pandemic.

Amy Summers, PharmD, BCSCP, consultant at Restore Health Consulting, discusses her CPhT 2021 conference presentation regarding proposed changes to the USP <795> and <797>.

Gary Locke, former governor of Washington state, US Secretary of Commerce, and ambassador to China, discusses the World Trade Organization's TRIPS Council, which recently met to assess the elimination of IP protections for COVID-19 vaccines, diagnostics, and medical devices.

Walgreens Chief Medical Officer Kevin Ban, MD, said the Walgreens 2021-2022 Flu Index is showing high flu activity in several regions of the country.

Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses his SOHO 2021 conference presentation on prognostication and treatment of Burkitt lymphoma in the modern era.

World Standards Week is October 25 to 29, so Pharmacy Times interviewed Jaap Venema, PhD, EVP and CSO at USP, on some of the key shifts that have occurred in USP’s standards development during the COVID-19 pandemic.

Kristen Demundo, PharmD, addresses the safety and efficacy of some topical agents used as therapy options for atopic dermatitis.

Pharmacy Times spoke with neurologist Dr. Tirisham Gyang and pharmacist Dr. Margaret Hansen about multiple sclerosis, including diagnosis, treatment options, and the role of the pharmacist in patient care.

Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains the initial management process for oncologic emergencies, the treatments currently available, and treatments coming in the drug pipeline.

Jennifer Andrews, MD, pediatric hematologist-oncologist at Vanderbilt University Medical Center and medical director of Vanderbilt University Medical Center’s blood bank, discusses how a national blood shortage could affect patient care and outcomes.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential drug-drug interactions with psilocybin, MDMA, and ketamine to consider outside of interactions with psychiatric medications.

In an interview with Pharmacy Times®, Jennifer Pena, chief medical officer for Nurx, discusses the impact of sexual health stigma, as well as how to combat it.

Payton Nyquvest, CEO and founder of Numinus, said he believes psychedelic medicines will lead to a significant shift in the mental health treatment landscape in the next 3 to 5 years.

Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains what the most common complications from cancer treatment are that can lead to oncologic emergencies and how can they be identified.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses the situations in which serotonin syndrome may be an area of concern when treating patients on psychiatric medication with psychedelic medicine.

In an interview with Pharmacy Times®, Lee Helman, MD, vice chair on Stand Up To Cancer's Scientific Advisory Committee, discusses the research collaboration between Stand Up To Cancer and Jazz Pharmaceuticals.

Melissa Pein, a pharmacy technician supervisor at Children’s Mercy Kansas City Hospital, discusses her CPhT 2021 conference presentation regarding pharmacy technicians and the role they play in vaccinations

In addition to her own work as a pharmacist, Michele Belcher, RPh said she learned about the value of pharmacy from her father, who was also a pharmacist involved with NCPA.

The #PizzaIsNotWorking campaign originated because free pizza or other mundane incentives do not adequately address the unrealistic expectations in pharmacies, which lead to an emphasis on metrics rather than patient safety.

Bhavesh Shah, RPh, BCOP, reviews data and results from the ARIEL3 trial that studied the PARP inhibitor, rucaparib, for the management of ovarian cancer.